As previously reported, BofA analyst Greg Harrison downgraded Beam Therapeutics to Neutral from Buy with a price target of $35, down from $45. While still positive on Beam’s underlying platform for SCD and AATD, the firm notes that the market is “currently giving little credit to companies with distant derisking events” and thinks the stock “could trade sideways over the next year” given the time needed until “truly derisking” clinical data is reported.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
- Qualcomm downgraded, First Solar upgraded: Wall Street’s top analyst calls
- Beam Therapeutics just downgraded at Jefferies, here’s why
- Beam Therapeutics price target lowered to $26 from $35 at Barclays
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results